Global Blood Therapeutics, Inc. (GBT)

NASDAQ: GBT · IEX Real-Time Price · USD
25.23
-0.45 (-1.75%)
May 25, 2022 4:00 PM EDT - Market closed
Market Cap1.64B
Revenue (ttm)210.87M
Net Income (ttm)-309.58M
Shares Out65.10M
EPS (ttm)-4.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,149,160
Open25.59
Previous Close25.68
Day's Range24.50 - 25.97
52-Week Range22.67 - 41.73
Beta1.09
AnalystsBuy
Price Target61.84 (+145.1%)
Earnings DateMay 4, 2022

About GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, wh...

IndustryBiotechnology
Founded2011
CEOTed Love
Employees457
Stock ExchangeNASDAQ
Ticker SymbolGBT
Full Company Profile

Financial Performance

In 2021, GBT's revenue was $194.75 million, an increase of 57.31% compared to the previous year's $123.80 million. Losses were -$303.09 million, 22.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for GBT stock is "Buy." The 12-month stock price forecast is 61.84, which is an increase of 145.11% from the latest price.

Price Target
$61.84
(145.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Global Blood Therapeutics Stock Was Sickly Today

The bears pounced on the company despite a first-quarter bottom-line beat.

2 weeks ago - The Motley Fool

Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

2 weeks ago - Zacks Investment Research

Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

GBT Reports First Quarter 2022 Financial Results

Achieved Oxbryta ® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year

3 weeks ago - GlobeNewsWire

GBT Launches Inaugural Environmental, Social and Governance (ESG) Report

Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity, Equity and Inclusion and Corporate Governance Report Highlights Efforts to Deliver Lo...

3 weeks ago - GlobeNewsWire

Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2022, the compensation committee of GBT's board of di...

1 month ago - GlobeNewsWire

Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim ...

2 months ago - GlobeNewsWire

The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community...

Grant proposals accepted through April 22, 2022 Grant proposals accepted through April 22, 2022

2 months ago - GlobeNewsWire

GBT Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following inv...

2 months ago - GlobeNewsWire

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

3 months ago - Zacks Investment Research

Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

GBT Reports Fourth Quarter and Full Year 2021 Financial Results

Achieved Oxbryta ® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year

3 months ago - GlobeNewsWire

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Other symbols:BHCBMRNCLVSTBPH
3 months ago - Zacks Investment Research

GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial results...

3 months ago - GlobeNewsWire

Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 year...

3 months ago - Benzinga

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell ...

The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell dise...

3 months ago - GlobeNewsWire

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics

Benzinga's weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the duel...

Other symbols:AXSM
3 months ago - Benzinga

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT's Voxelotor for the Treatment of H...

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opini...

3 months ago - GlobeNewsWire

12 Super Small-Cap Stocks to Buy for 2022 and Beyond

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

4 months ago - Kiplinger

GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conferen...

4 months ago - GlobeNewsWire

Global Blood (GBT) Gets FDA Nod for Oxbryta Label Expansion

The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.

5 months ago - Zacks Investment Research

GBT's Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sick...

European Commission decision on marketing authorization anticipated first quarter of 2022

5 months ago - GlobeNewsWire